ArticleOncoTargets and therapy2016

Can we avoid dose escalation for intermediate-risk prostate cancer in the setting of short-course neoadjuvant androgen deprivation?

Thomas P Shakespeare et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.